Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK‐3475) in the treatment of adult participants with unresected stage I or II (Stage IIB N0, M0) non‐small cell lung cancer (NSCLC). The primary study hypothesis is SBRT plus pembrolizumab prolongs Event‐free Survival (EFS) compared to SBRT plus placebo (normal saline solution).
Epistemonikos ID: ee7f880c95609317bd1158b4a31ba0e114aaa836
First added on: May 22, 2024